Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes

NCT02607865 on ClinicalTrials.gov · last registry update 2022-07-20

An unusually large phase 3: 1,864 participants, more than double the 424 typical for the stage. The sponsor logged completion for 14 February 2017. Primary outcome, as filed: Change in HbA1c: Week 26. semaglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 1,864
Started: 2016-02-15
Primary completion: 2017-02-14 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in HbA1c: Week 26

Conditions studied

Diabetes · Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.